Vision-2 follows successful Vision-1 trial with expected top-line results in Q2 2022
Presbyopia represents a multi-billion-dollar market opportunity in the U.S. alone
NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the first patient has been enrolled in the Company’s second Phase 3 clinical trial of MicroLine, its proprietary pilocarpine formulation for temporary improvement in near vision (presbyopia), known as VISION-2.
“Following the completion of VISION-1 study, we are pleased to initiate this second Phase 3 trial that, if successful, will contribute to the clinical evidence supporting a new drug/device combination application to the US FDA,” stated Sean Ianchulev, Chief Executive Officer and Chief Medical Officer of Eyenovia. “By leveraging the numerous benefits of our microdose array print (MAP™) technology, we believe MicroLine has the potential to be among the first drug treatments to improve blurred near vision that can adversely impact quality of life in patients with presbyopia.”
“Additionally, with 18 million people between the ages of 40 and 55 in the US afflicted with presbyopia, this is a significant market opportunity for our company – in excess of several billion dollars according to very recent third-party market research. We look forward to continuing to advance this promising and differentiated therapeutic through late-stage development for the potential benefit of patients, eye care practitioners and shareholders alike.”
The VISION-2 study is a double-masked, placebo-controlled, cross-over superiority trial in which approximately 140 subjects with presbyopia will be treated. During the study, subjects will be randomly assigned to a treatment sequence for dosing with pilocarpine 2% as well as placebo, both administered via the Optejet™ dispenser. The primary endpoint is improvement in high contrast binocular distance corrected near visual acuity measured in low light conditions 2 hours after treatment. Topline data is expected in mid-2022.
In May 2021, Eyenovia announced positive results from the first Phase 3 MicroLine study, VISION-1. In that trial, the primary endpoint was achieved with MicroLine 2% statistically superior to placebo, determined by improvement in high contrast binocular distance corrected near visual acuity measured in low light conditions 2 hours after treatment. Further, MicroLine was very well tolerated; adverse events reported were all mild and transient in nature including fewer than 3% of patients reporting brow/headache. In a post-study survey, 70% of study participants reported strong interest in using MicroLine for near vision improvement should it be approved. These patients said they would expect to use the product three to four times per week on average.
About the VISION Trials
The VISION trials are Phase 3, double-masked, placebo-controlled, cross-over superiority trials that enroll participants with presbyopia. The primary endpoint is improvement in high-contrast binocular distance corrected near visual acuity in low light conditions. MicroLine is intended for the “on demand” improvement of near vision in people with presbyopia.
About MicroLine for Presbyopia
MicroLine (pilocarpine ophthalmic solution) is Eyenovia’s investigational pharmacologic treatment for presbyopia. Presbyopia or farsightedness is the non-preventable, age-related hardening of the lens, which causes a gradual loss of the eye’s ability to focus on nearby objects and is estimated to affect nearly 113 million Americans. Treatment options are typically device-based, such as reading glasses and contact lenses. Pilocarpine ophthalmic solution is known to constrict the pupil and improve near-distance vision by creating an extended depth of focus through its small aperture effect. Eyenovia believes that its administration of pilocarpine using the Company’s high precision microdosing technology could provide a meaningful improvement in near vision while enhancing tolerability and usability. MicroLine has been licensed to Arctic Vision (Hong Kong) Limited in Greater China and South Korea.
About MicroPine for Progressive Myopia
MicroPine (atropine ophthalmic solution) is Eyenovia’s investigational, potentially first-in-class topical treatment for the reduction of pediatric myopia progression, also known as nearsightedness, in children ages 3-12. It has been developed for comfort and ease-of-use in children, and its microdose administration is designed to potentially result in low systemic and ocular drug exposure. MicroPine has been licensed to Bausch Health Companies, Inc. in the United States and Canada, and Arctic Vision (Hong Kong) Limited in Greater China and South Korea.
About MydCombi™ for Mydriasis
MydCombi is Eyenovia's investigational, first-in-class fixed-dose-combination product (tropicamide 1% and phenylephrine 2.5% ophthalmic solution) for pharmacologic mydriasis (eye dilation), which is targeted to improve the efficiency of the estimated 100 million office-based comprehensive eye exams performed every year in the United States, as well as the estimated 4 million pharmacologic mydriasis applications for cataract surgery. Developed as a micro-formulation for use without anesthetic, Eyenovia believes MydCombi will help improve the efficacy, tolerability, and efficiency of pharmacologic mydriasis. MydCombi has been licensed to Arctic Vision (Hong Kong) Limited in Greater China and South Korea.
About Optejet® and Microdose Array Print (MAP™) Therapeutics
Eyenovia's Optejet microdose formulation and delivery platform for ocular therapeutics uses high-precision piezo-print technology to deliver 6-8 μL of drug, consistent with the capacity of the tear film of the eye. We estimate the volume of ophthalmic solution administered with the Optejet is less than 20% of that delivered using conventional eyedroppers, thus reducing overdosing and exposure to drug and preservatives. Eyenovia's patented microfluidic ejection technology is designed for fast and gentle ocular surface delivery, where solution is dispensed to the ocular surface in approximately 80 milliseconds, beating the ocular blink reflex. Successful use of the Optejet has been demonstrated more than 85% of the time after basic training in a variety of clinical settings compared to 40 – 50% historically seen with conventional eyedroppers. Additionally, its smart electronics and mobile e-health technology are designed to track and enhance patient compliance.
About Eyenovia, Inc.
Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia and myopia progression. For more information, visit Eyenovia.com.
The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.
Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19 and resulting social distancing), timing, progress and results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals for our product candidates; the potential impacts of COVID-19 on our supply chain; the potential advantages of our product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; reliance on third parties to develop and commercialize our product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our product candidates; intellectual property risks; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements.
Chief Financial Officer
Eyenovia Investor Contact:
LifeSci Advisors, LLC
Eyenovia Media Contact:
Pazanga Health Communications
Accord Financial Corp. (TSX: ACD) today released its financial results for the three and nine months ended September 30, 2021. The financial figures presented in this release are reported in Canadian dollars and have been prepared in accordance with International Financial Reporting Standards.
TGS Esports Inc. ("TGS" or the "Company") (TSXV: TGS) (OTCQB: TGSEF) (FRA: 5RH) announces that the British Columbia Securities Commission (the "BCSC") has issued a Cease Trade Order (the "CTO") as a result of the Company's failure to file its audited financial statements for its year ended June 30, 2021 and related management's discussion and analysis (collectively, the "Annual Filings") by October 28, 2021, being the date that such filings were due under applicable Canadians securities law requ
Universal Ibogaine Inc. (TSXV: IBO) ("Universal Ibogaine", "UI" or the "Company"), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, is pleased to announce an expansion of its Executive Team and welcomes addiction treatment and clinic operations veteran Dr Ian Rabb as Chief Clinics Officer effective November 15, 2021.
(Reuters) -CVS Health Corp on Wednesday said its adjusted profit target for 2022 should largely meet Wall Street estimates, as it expects volatile medical costs in its health insurance unit to stabilize after the COVID-19 crisis drove them up this year. "We believe that current analyst estimates for 2022 adjusted EPS of approximately $8.20 are within our anticipated initial guidance range," Chief Financial Officer Shawn Guertin told analysts on a conference call. CVS in August https://reut.rs/3BBWfXf had hedged a bit on its long-term target for double digit earnings growth for 2022, pointing to uncertainty around medical costs and COVID-19 testing and vaccine demand.
How far off is A10 Networks, Inc. ( NYSE:ATEN ) from its intrinsic value? Using the most recent financial data, we'll…
With pharma stock AbbVie (NYSE: ABBV) set to lose U.S. exclusivity for its immunology drug Humira in 2023, analysts believe that Merck's (NYSE: MRK) cancer drug Keytruda will soon claim Humira's crown as the top-selling medicine in the world. Keytruda recently advanced down that road with a major regulatory approval. In late October, the European Commission (EC) approved it in combination with chemotherapy to treat patients with locally recurrent, unresectable or metastatic triple-negative breast cancer (TNBC) in the European Union (E.U.).
Based on analysts' loftiest price targets, these drugmakers could double to nearly quintuple investors' money over the next 12 months.
(Reuters) -Vaccine developer Novavax Inc said on Thursday it has completed the submission process for emergency use listing of its COVID-19 vaccine candidate with the World Health Organization. The company submitted to the health agency all modules required for the evaluation of NVX-CoV2373, its protein-based COVID-19 vaccine, days after receiving its first emergency use authorization from Indonesia. "The first authorization of the COVID-19 vaccine… will fill a vital need for Indonesia, which is the fourth most populous nation on earth and continues to work to procure sufficient vaccine for its population," Chief Executive Stanley Erck said during an investor call.
It appears that Pfizer has taken the lead in the tug of war for market share among the leading COVID-19 vaccine makers, and Moderna's investors aren't happy about it.
The stock was off by about 12% in early trading as sales of the company's only product, a Covid-19 vaccine, fell short of expectations by more than $1 billion.
Merck's Covid-19 pill was just approved in the U.K. The company's agreement with a patent-sharing pool is a model for medical equity, writes Ellen 't Hoen, the pool's founder.
Moderna Inc. expects to deliver fewer Covid-19 vaccines than originally anticipated by the end of the fiscal year. The company says much of this is due to longer lead times for international deliveries as it shifts its priorities.
In this article, we discuss the 10 best cancer stocks to buy now. If you want to skip our detailed analysis of these companies and the outlook for the oncology sector, go to the 5 Best Cancer Stocks To Buy Now. The global oncology pharmaceutical market experienced a tailwind amid the COVID-19 pandemic. Cancer revenue grew […]
Which businesses must require workers get vaccinated for COVID-19 or be regularly tested? Who is covered by the rules? Here's what you need to know.
Gal Gadot showed off her incredibly sculpted legs at the 'Red Notice' premiere in Los Angeles. Regular HIIT workouts keep her strong and in shape.
CDC Director Rochelle Walensky endorsed Pfizer's Covid vaccine for young children. But Pfizer stock fell Wednesday.
"IT'S MY BIRTHDAY, BABY!" Kathy Griffin wrote on Instagram, celebrating her 61st birthday with a topless dance on her balcony
You feel sick. Is it a cold, flu, allergies, COVID-19, or the highly contagious Delta variant? According to Inci Yildirim, MD, Ph.D., a Yale Medicine pediatric infectious diseases specialist and a vaccinologist, Delta seems to affect the body a little differently than other strains, especially when it comes to symptoms. "This variant seems to be working slightly differently," adds virus expert Tim Spector, who's ZOE Symptom Project in the UK has been tracking symptoms. "So I think the message he
Moderna (NASDAQ: MRNA) and rival Pfizer (NYSE: PFE) dominate the coronavirus vaccine market. Pfizer won authorization in the teen market in May. And the U.S. Food and Drug Administration (FDA) offered Pfizer authorization in kids ages 5 through 11 late last month. Moderna, however, has hit a stumbling block.
Novavax (NASDAQ:NVAX) is racing to obtain approvals from the World Health Organization (WHO) and the U.S. Food and Drug Administration (FDA) for its Covid-19 vaccine NVX-CoV2373. Understandably, investors have balked at these delays, sending the NVAX stock price down considerably from its 52-week high. Source: Ascannio/Shutterstock.com Considering the delays and manufacturing issues, many might feel NVAX stock is yesterday’s news. But the vaccine race is not over. Several developing countries ar